The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus

• Published in: World journal of urology Vol. 42; no. 1; p. 10
• Main Authors: Liao, Zhangcheng, Li, Jiao, Zhao, Yang, Wang, Zhan, Wang, Xu, Qiu, Dongxu, Zhang, Yushi
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 06.01.2024; Springer Nature B.V
• Subjects: Age; Angiomyolipoma; Clinical trials; Computed tomography; Correlation analysis; Gender; Kidneys; Medicine; Medicine & Public Health; Nephrology; Oncology; Original Article; Patients; Tomography; Tuberous sclerosis; Tumors; Urology; Renal angiomyolipoma; Computed tomography attenuation value; Everolimus; Tuberous sclerosis complex
• ISSN: 1433-8726; 0724-4983; 1433-8726
• DOI: 10.1007/s00345-023-04708-1

Background The response to everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC-RAML) varies among individuals. This study aims to identify potential factors associated with the response to everolimus. Method We retrospectively examined data encompassing age, gender, tumor size, computed tomography attenuation value (CT value), CT enhancement, and tumor reduction rate in patients with TSC-RAML undergoing everolimus in two previously registered clinical trials. Result A total of 33 participants (29.33 ± 6.63 years old, 20 females) were included. The correlation analysis conducted separately for tumors located in the left and right kidneys revealed significant negative correlations ( P  < 0.05) between tumor reduction rate and age, as well as tumor size. While significant positive correlations ( P  < 0.05) were observed between tumor reduction rate and unenhanced CT value as well as CT enhancement. Nonetheless, based on multiple linear regression analysis, unenhanced CT value emerged as the sole-independent predictor of tumor reduction rate among age, gender, tumor size, unenhanced CT value and CT enhancement for both left (coefficient = 0.00319, P  < 0.0001) and right kidneys (coefficient = 0.00315, P  = 0.0104). Notable reductions were observed in unenhanced CT value (− 3.81 vs − 24.70HU, P  < 0.0001) and CT enhancement (48.16 vs 33.56HU, P  < 0.0001) following a 3-month administration of everolimus. The decline in both unenhanced CT value and tumor size predominantly occurred within the initial 3 months, subsequently maintaining a relatively stable level throughout the treatment. Conclusion The unenhanced CT value of TSC-RAML showed an independent correlation with the response to everolimus, suggesting its potential as a predictor of everolimus efficacy in patients with TSC-RAML.